Product Launch Opportunity to engage with Oyster Point Pharma around Tyrvaya and future ophthalmic therapies, leveraging their first-in-class approach to expand portfolio partnerships and contract opportunities with payers, distributors, and healthcare providers.

Commercial Stage As a commercial-stage biopharma with FDA-approved nasal spray for dry eye disease and revenue in the early-to-mid tens of millions, there is potential for channel expansion, co-promotion, and data-driven access strategies with specialty eye care networks.

Compliance & Governance Recent leadership promotions and board activity signal emphasis on governance and ethics; propose solutions that streamline compliance, risk monitoring, and vendor due diligence to support scale and potential M&A engagement with Viatris or other partners.

Digital & Ops Existing tech stack (Power BI, AWS, SharePoint, Salesforce, NetSuite, Azure, Office 365) opens doors for managed services, data integration, CRM optimization, and cloud-based operations partnerships to improve commercial execution and reporting.

Financial Trajectory Funding level and revenue range indicate readiness for strategic partnerships, licensing, or co-development deals; target opportunities around supply chain optimization, manufacturing scalability, or regional distribution arrangements to support growth.